Abstract:Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe clinical conditions with a high mortality rate. Nucleotide‑binding oligomerization domain (NOD)‑like receptor containing pyrin domain 3 (NLRP3) and nuclear factor E2‑related factor 2 (Nrf2) have been reported to be associated with ALI. However, the dynamic changes in the levels of these factors in lipopolysaccharide (LPS)‑induced lung injury remain unclear. Thus, the present study aimed to determine the LPS‑induced activation of immunological cascades, as well as the NLRP3/Nrf2 signaling pathway at different stages of lung injury. For this purpose, mice were divided into six groups as follows: The control, LPS‑4 h, LPS‑24 h, LPS‑48 h, LPS‑96 h and LPS‑144 h groups. LPS (4 mg/kg) was administered intratracheally to induce lung injury. Flow cytometry was used to determine the changes in macrophages, neutrophils and T‑cell subsets in lung tissue, hematoxylin and eosin staining were used to measure the histopathological changes in lung tissues, ELISA was performed to evaluate the levels of cytokines, western blot analysis was used to measure the levels of inflammatory proteins, and reverse transcription‑quantitative PCR used to determine the mRNA level of a target gene. Following LPS administration, evident histopathological damage with neutrophil infiltration was observed which peaked at 48 h. The levels of interleukin‑1β, keratinocyte‑derived chemokine, macrophage inflammatory protein 2 and tumor necrosis factor a were markedly increased in bronchoalveolar lavage fluid and serum from the mice, and these levels peaked at 4 h. Moreover, LPS promoted Toll like receptor‑4 expression and reactive oxygen species production, thus activating NLRP3/Nrf2 signaling and pyroptosis. Collectively, the present study demonstrates that LPS triggers multiple inflammatory molecules and immune cells during ALI, which may be closely involved in the irregular redox status, NLRP3/Nrf2 pathway and pyroptosis.

MiR-150 Attenuates LPS-induced Acute Lung Injury Via Targeting AKT3.

Time‑dependent changes in NLRP3 and Nrf2 levels in lipopolysaccharide‑induced acute lung injury

Mir-150 and SRPK1 Regulate AKT3 Expression to Participate in LPS-induced Inflammatory Response

Downregulation Of Mir-199a-3p Mediated By The Ctbp2-Hdac1-Foxp3 Transcriptional Complex Contributes To Acute Lung Injury By Targeting Nlrp1

Upregulation of Mir-146a Contributes to the Suppression of Inflammatory Responses in Lps-Induced Acute Lung Injury

MiR-146a alleviates acute lung injury via inhibiting Notch 1 signaling pathway targeting macrophage

miRNA-206-3p alleviates LPS-induced acute lung injury via inhibiting inflammation and pyroptosis through modulating TLR4/NF-κB/NLRP3 pathway

Mir‐146b Overexpression Ameliorates Lipopolysaccharide‐induced Acute Lung Injury in Vivo and in Vitro

Downregulation of TLR4 by Mir-181A Provides Negative Feedback Regulation to Lipopolysaccharide-Induced Inflammation

MiR-297 Alleviates LPS-induced A549 Cell and Mice Lung Injury Via Targeting Cyclin Dependent Kinase 8

Exosomal Mir-150 Partially Attenuated Acute Lung Injury by Mediating Microvascular Endothelial Cells and MAPK Pathway

MiR-30a-5p Ameliorates LPS-induced Inflammatory Injury in Human A549 Cells and Mice Via Targeting RUNX2

Mir-497A-5p Attenuates Lipopolysaccharide-Induced Inflammatory Injury by Targeting IRAK2.

Enforced Expression of Mir-125B Attenuates LPS-induced Acute Lung Injury

MicroRNA-31-5p Exacerbates Lipopolysaccharide-Induced Acute Lung Injury Via Inactivating Cab39/AMPKα Pathway

LncRNA XIST Knockdown Alleviates LPS-induced Acute Lung Injury by Inactivation of XIST/miR-132-3p/MAPK14 Pathway

Macrophage Micro-Rna-155 Promotes Lipopolysaccharide-Induced Acute Lung Injury in Mice and Rats

MicroRNA-23a-5p is Involved in the Regulation of Lipopolysaccharide-Induced Acute Lung Injury by Targeting HSP20/ASK1.

Inhibition of miR-221 alleviates LPS-induced acute lung injury via inactivation of SOCS1/NF-κB signaling pathway.

The function and mechanism of microRNA-92a-3p in lipopolysaccharide-induced acute lung injury

miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury.